Immuno-Oncology | Specialty

Dr. Usmani on Potential of Checkpoint Inhibitors in Multiple Myeloma

September 7th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the potential of checkpoint inhibitors as monotherapy and in combination.

FDA Halts Enrollment on 3 Nivolumab Myeloma Trials

September 7th 2017

The FDA has placed partial clinical holds on 3 trials assessing nivolumab (Opdivo)-based combinations in patients with relapsed/refractory multiple myeloma.

Update Confirms Benefit of Pembrolizumab Plus Indoximod in Melanoma

September 7th 2017

Adding the IDO inhibitor indoximod to pembrolizumab (Keytruda) led to an overall response rate of 61% in patients with advanced melanoma.

Dr. Bunn on the Response of Immunotherapy in Lung Cancer

September 7th 2017

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the response of immunotherapy in patients with lung cancer.

Pembrolizumab Approved in Europe for Urothelial Carcinoma

September 6th 2017

The European Commission has approved pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy, or who are not eligible for cisplatin-containing chemotherapy.

Dr. Riess on the Long-Term Benefit With Immunotherapy for Lung Cancer

September 1st 2017

Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

FDA Discloses Data on Halted Pembrolizumab Myeloma Trials

September 1st 2017

The FDA released a statement today providing specific data from 2 phase III trials of pembrolizumab in multiple myeloma that the agency placed clinical holds on in July.

Liquid Biopsy for NSCLC: Emerging Developments

August 29th 2017

Future Directions for Liquid Biopsy in NSCLC

August 29th 2017

Liquid Biopsy and Next-Generation Sequencing

August 29th 2017

Interpretation of NSCLC Plasma Genotyping Results

August 29th 2017

Liquid Biopsy: Differences Among Technologies

August 29th 2017

Plasma Genotyping Platforms: Strengths and Limitations

August 29th 2017

Plasma Testing for NSCLC EGFR & ALK Mutations

August 29th 2017

Clinical Applications for NSCLC Liquid Biopsy

August 29th 2017

How Does Liquid Biopsy Work?

August 29th 2017

The Role for Liquid Biopsy in NSCLC

August 29th 2017

Widespread Mutation Testing for NSCLC

August 29th 2017

Genetic Testing for NSCLC

August 29th 2017

Optimizing Immunotherapy Remains a Challenge in NSCLC

August 29th 2017

David R. Gandara, MD, discusses the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.